Bacteria Patents (Class 530/825)
  • Patent number: 9034345
    Abstract: The present invention generally provides methods and compositions for eliciting an immune response against Neisseria spp. bacteria in a subject, particularly against a Neisseria meningitidis serogroup B strain.
    Type: Grant
    Filed: January 23, 2006
    Date of Patent: May 19, 2015
    Assignee: Children's Hospital & Research Center Oakland
    Inventors: Dan M. Granoff, Victor Chen-Hsi Hou
  • Patent number: 9006395
    Abstract: A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide, is possible and the polypeptide can be incorporated into vaccines and toxin assays.
    Type: Grant
    Filed: October 7, 2010
    Date of Patent: April 14, 2015
    Assignee: The Secretary of State for Health
    Inventors: Clifford Charles Shone, Keith Alan Foster, John Chaddock, Philip Marks, J. Mark Sutton, Patrick Stancombe, Jonathan Wayne
  • Patent number: 8968748
    Abstract: The present invention generally provides methods and compositions for eliciting an immune response against Neisseria spp. bacteria in a subject, particularly against a Neisseria meningitidis serogroup B strain.
    Type: Grant
    Filed: October 21, 2011
    Date of Patent: March 3, 2015
    Assignee: Children's Hospital & Research Center Oakland
    Inventors: Dan M. Granoff, Victor Chen-Hsi Hou
  • Patent number: 8957028
    Abstract: The invention, in some aspects, relates to compositions and methods for altering cell activity and function. The invention also relates, in part, to the use of light-activated ion pumps (LAIPs) such as a light-activated ion pump polypeptide that when expressed in an excitable cell and contacted with a red light silences the excitable cell, wherein the polypeptide sequence of the light-activated ion pump comprises a wild-type or modified halomicrobium or haloarcula halorhodopsin polypeptide sequence.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: February 17, 2015
    Assignee: Massachusetts Institute of Technology
    Inventors: Amy Chuong, Nathan Klapoetke, Brian Yichiun Chow, Edward Boyden, Xue Han
  • Patent number: 8945589
    Abstract: This application relates to Group B Streptococcus (“GBS”) vaccines comprising combinations of GBS polypeptide antigens where the polypeptides contribute to the immunological response in a recipient. Preferably, the compositions of the invention comprise a combination of two or more GBS antigens, wherein said combination includes GBS 80 or a fragment thereof. In one embodiment, the combination may consist of two to thirteen GBS antigens selected from an antigen group consisting of GBS 80, GBS 91, GBS 104, GBS 184, GBS 276, GBS 305, GBS 322, GBS 330, GBS 338, GBS 361, GBS 404, GBS 690, and GBS 691.
    Type: Grant
    Filed: September 15, 2004
    Date of Patent: February 3, 2015
    Assignee: Novartis Vaccines and Diagnostics, SRL
    Inventors: John Telford, Guido Grandi, Immaculada Margarit Y Ros, Domenico Maione
  • Patent number: 8932609
    Abstract: The use of flagellin and flagellin related polypeptides for the protection of mammals from the effects of apoptosis is described.
    Type: Grant
    Filed: May 18, 2011
    Date of Patent: January 13, 2015
    Assignee: Cleveland Clinic Foundation
    Inventors: Andrei V. Gudkov, Joseph A. DiDonato, Vadim Krivokrysenko
  • Patent number: 8926959
    Abstract: Stimulation of target cells using light, e.g., in vivo, is implemented using a variety of methods and devices. According to an example embodiment of the present invention, target cells are stimulated using an implantable arrangement. The arrangement includes an electrical light-generation means for generating light and a biological portion. The biological portion has a photosensitive bio-molecular arrangement that responds to the generated light by stimulating target cells in vivo.
    Type: Grant
    Filed: January 9, 2007
    Date of Patent: January 6, 2015
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Karl Deisseroth, M. Bret Schneider, David J. Mishelevich
  • Patent number: 8926990
    Abstract: This invention concerns compositions and methods of treating or diagnosing inflammatory disorders and other disorders, as well as compositions and methods of treating HIV.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: January 6, 2015
    Assignee: Rutgers, The State University of New Jersey
    Inventor: Scott C. Kachlany
  • Patent number: 8926989
    Abstract: The invention provides compositions, methods, and kits for the diagnosis or detection of infection by a pathogen that causes Lyme disease in a subject.
    Type: Grant
    Filed: March 10, 2011
    Date of Patent: January 6, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter D. Burbelo, Adriana Marques, Michael J. Iadarola
  • Patent number: 8911748
    Abstract: The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of Staphylococcus aureus. One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen having at least one of: an antigenic material from S. aureus and an antigenic material from a S. aureus-specific polypeptide.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: December 16, 2014
    Assignee: Boise State University
    Inventor: Juliette Tinker
  • Patent number: 8871215
    Abstract: The use of flagellin and flagellin related polypeptides for the protection of mammals from the effects of apoptsis is described.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: October 28, 2014
    Assignee: Cleveland Clinic Foundation
    Inventors: Andrei V. Gudkov, Joseph A. DiDonato, Vadim Krivokrysenko
  • Patent number: 8858957
    Abstract: The invention provides mutants of GAS57 (Spy0416) which are unable to cleave IL-8 and similar substrates but which still maintain the ability to induce protection against S. pyogenes. The invention also provides antibodies which specifically bind to GAS57 and which inhibit its ability to cleave IL-8 and similar substrates. The mutants are useful, inter alia, in vaccine compositions to induce protection against S. pyogenes. The antibodies are useful, e.g., as therapeutics for treating S. pyogenes infections.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: October 14, 2014
    Assignee: Novartis AG
    Inventors: Immaculada Margarit Y Ros, Guido Grandi, Chiara Zingaretti
  • Patent number: 8834898
    Abstract: The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of Staphylococcus aureus. One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen having at least one of an antigenic material from S. aureus and an antigenic material from a S. aureus-specific polypeptide.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: September 16, 2014
    Assignee: Boise State University
    Inventor: Juliette Tinker
  • Patent number: 8754196
    Abstract: The present invention relates to chromatography matrices including ligands based on one or more domains of immunoglobulin-binding proteins such as, Staphylococcus aureus Protein A (SpA), as well as methods of using the same.
    Type: Grant
    Filed: June 6, 2012
    Date of Patent: June 17, 2014
    Assignee: EMD Millipore Corporation
    Inventors: Shari Spector, Robert Smith, Joe Orlando, Nanying Bian
  • Patent number: 8734812
    Abstract: This invention provides, among other things, proteins, polypeptides, and fragments thereof, derived from the bacteria Neisseria meningitidis B. Also provided are nucleic acids encoding for such proteins, polypeptides, and/or fragments, as well as nucleic acids complementary thereto (e.g., antisense nucleic acids). Additionally, this invention provides antibodies which bind to the proteins, polypeptides, and/or fragments. This invention further provides expression vectors useful for making the proteins, polypeptides, and/or fragments, as well as host cells transformed with such vectors. This invention also provides compositions of the proteins, polypeptides, fragments, and/or nucleic acids, for use as vaccines, diagnostic reagents, immunogenic compositions, and the like. Methods of making the compositions and methods of treatment with the compositions are also provided. This invention also provides methods of detecting the proteins, polypeptides, fragments, and/or nucleic acids.
    Type: Grant
    Filed: October 30, 2000
    Date of Patent: May 27, 2014
    Assignee: Novartis AG
    Inventors: Cesira Galeotti, Guido Grandi, Vega Masignani, Mariarosa Mora, Mariagrazia Pizza, Rino Rappuoli, Guilio Ratti, Vincenzo Scarlato, Maria Scarselli
  • Patent number: 8709436
    Abstract: The present invention provides isolated polypeptides isolatable from a Staphylococcus spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.
    Type: Grant
    Filed: March 18, 2008
    Date of Patent: April 29, 2014
    Assignee: Epitopix, LLC.
    Inventors: Daryll A. Emery, Darren E. Straub, Laura Wonderling, Lisa L. Herron Olson
  • Patent number: 8691243
    Abstract: Vaccine compositions and methods for protecting a mammalian subject against infection with S. pneumoniae are disclosed. The vaccines and methods comprise an effective amount of one or more Streptococcus pneumoniae cell wall and/or cell membrane proteins and/or immunogenically-active fragments, derivatives or modifications thereof, wherein the proteins are selected from a defined group of proteins associated with age-dependent immunological responses.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: April 8, 2014
    Assignee: Ben-Gurion University of the Negev Research and Development Authority
    Inventor: Yaffa Mizrachi Nebenzahl
  • Patent number: 8679510
    Abstract: The present invention features peptides of a PorB polypeptide, which PorB peptides are useful in production of antibodies that bind the full-length PorB polypeptide and as a therapeutic agent. In specific embodiments the invention features a composition comprising one or more PorB peptides (other than a full-length PorB polypeptide), which peptides contain at least one epitope that can elicit Chlamydia-neutralizing antibodies. The invention also features methods for induction of a protective immune response against infection by Chlamydia and Chlamydiophila.
    Type: Grant
    Filed: November 20, 2012
    Date of Patent: March 25, 2014
    Assignee: The Regents of the University of California
    Inventors: Richard S. Stephens, Diane Kawa
  • Patent number: 8674077
    Abstract: The present invention relates to methods of producing silk dope comprising silk proteins with a coiled-coil structure such as honeybee silk proteins. The silk proteins are obtained from cells producing them, solubilizing the proteins by contacting them with a surfactant or an ionic liquid and concentrating the proteins to produce silk dope. The proteins can be used for a variety of purposes such as in the production of personal care products, plastics, textiles and biomedical products.
    Type: Grant
    Filed: August 25, 2010
    Date of Patent: March 18, 2014
    Assignee: Commonwealth Scientific and Industrial Research Organisation
    Inventors: Tara D. Sutherland, Victoria S. Haritos, Alagacone Sriskantha, Sarah Weisman, Michael George Huson, Jeffrey Scott Church
  • Patent number: 8642048
    Abstract: The invention provides a nucleic acid encoding the 37-kDa pneumococcal surface adhesion A protein (PsaA) from Streptococcus pneumoniae. The invention also provides purified polypeptides encoded by the nucleic acid encoding the 37-kDa protein from and the nucleic acids comprising unique fragment of at least 10 nucleotides of the 37-kDa protein. Additionally, multiple antigenic peptides that provide protection against S. pneumoniae challenge are provided. These multiple antigen peptides comprise the peptides that immunospecifically bind to the monoclonal antibodies. Also provided are vaccines comprising such immunogenic peptides, and methods of conferring protective immunity against Streptococcus pneumoniae infection by administering therapeutic composition comprising the immunogenic peptides of the invention.
    Type: Grant
    Filed: January 27, 2009
    Date of Patent: February 4, 2014
    Assignee: The United States of America, as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Edwin W. Ades, Scott E. Johnson, Danny L. Jue, Jacquelyn S. Sampson, George M. Carlone
  • Patent number: 8632784
    Abstract: Novel proteins from Streptococcus pneumoniae are described, together with nucleic acid sequences encoding them. Their use in vaccines and in screening methods is also described.
    Type: Grant
    Filed: June 7, 2006
    Date of Patent: January 21, 2014
    Assignee: Sanofi Pasteur Limited
    Inventors: Richard William Falla Le Page, Jeremy Mark Wells, Sean Bosco Hanniffy, Philip Michael Hansbro
  • Patent number: 8623383
    Abstract: The invention relates to the construction of recombinant, immunodominant polypeptides against spotted fever group Rickettsia. The invention also relates to a method for the use of the recombinant proteins, either singly or in combination, in detection and diagnostic assays of spotted fever. The proteins can also be used to induce immune response against spotted fever group Rickettsia.
    Type: Grant
    Filed: June 8, 2009
    Date of Patent: January 7, 2014
    Assignee: The United States of America as represented by the Secretary of the Navy
    Inventor: Wei-Mei Ching
  • Patent number: 8586832
    Abstract: The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of Bacillus thuringiensis encoding polypeptides having pesticidal activity against insect pests, including Lepidoptera. Particular embodiments of the invention provide isolated nucleic acids encoding pesticidal proteins, pesticidal compositions, DNA constructs, and transformed microorganisms and plants comprising a nucleic acid of the embodiments. These compositions find use in methods for controlling pests, especially plant pests.
    Type: Grant
    Filed: December 8, 2010
    Date of Patent: November 19, 2013
    Assignee: Pioneer Hi Bred International Inc
    Inventors: Andre R. Abad, Hua Dong, Deirdre M. Kapka-Kitzman, Sue B. Lo, Xiaomei Shi
  • Patent number: 8574597
    Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: November 5, 2013
    Assignee: Wyeth LLC
    Inventor: Gary Warren Zlotnick
  • Patent number: 8563007
    Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: October 22, 2013
    Assignee: Wyeth Holdings Corporation
    Inventors: Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
  • Patent number: 8563006
    Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: October 22, 2013
    Assignee: Wyeth Holdings Corporation
    Inventors: Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
  • Patent number: 8545853
    Abstract: It refers to a recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, comprising a deletion in the stem domain, wherein at least one heterologous sequence is inserted in a region selected from the group consisting of regions defined by amino acid position of 108 to 151, 1 to 5, 288 to 293, 43 to 48, 235 to 240, 92 to 97, 31 to 36,or 156 to 161 of SEQ ID NO: 1, with the proviso that, if the heterologous sequence contains five or more consecutive histidines the moiety of the heterologous sequence other than the moiety of five or more consecutive histidines has a minimum length of 11 amino acids; or a variant thereof comprising 1-50 amino acids added, substituted or deleted in SEQ ID NO. 1 and the activity to form oligomers and to bind to lipidic bilayers. It also provides a medicament and vaccine comprising said recombinant polypeptide.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: October 1, 2013
    Assignees: Universite de Liege, Centre d'Economie Rurale, Universite Libre de Bruxelles
    Inventors: Patrice Filee, Noureddine Rhazi, Moreno Galleni, Bernard Taminiau, Olivier Jolois, Alfred Collard, Alain Jacquet
  • Patent number: 8524251
    Abstract: The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: September 3, 2013
    Assignees: J. Craig Venter Institute, Inc., Novartis AG
    Inventors: Claire Fraser, Cesira Galeotti, Guido Grandi, Erin Hickey, Vega Masignani, Marirosa Mora, Jeremy Petersen, Mariagrazia Pizza, Rino Rappuoli, Giulio Ratti, Vincenzo Scarlato, Maria Scarselli, Herve Tettelin, J. Craig Venter
  • Patent number: 8501197
    Abstract: This invention provides a method for stimulating in an individual an immune response against M. catarrhalis. The method comprises administering to an individual a composition comprising M. catarrhalis OppA protein in an amount effective to stimulate an immune response against M. catarrhalis in the individual.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: August 6, 2013
    Assignee: The Research Foundation for The State of New York
    Inventors: Timothy F. Murphy, Min Yang
  • Patent number: 8470340
    Abstract: Polypeptides that can elicit antibodies that are bactericidal for different fHbp variant strains of N. meningitidis, and methods of use, are provided.
    Type: Grant
    Filed: September 2, 2009
    Date of Patent: June 25, 2013
    Assignees: Children's Hospital & Research Center Oakland, Novartis Vaccines and Diagnostics, SRL, Universita degli Studi del Molise
    Inventors: Peter Beernink, Franco Felici, Dan M. Granoff
  • Patent number: 8455620
    Abstract: The present invention relates to a novel phytase enzyme, a novel isolated nucleic acid molecule coding the enzyme, and a novel Yersinia intermedia having phytase activity. Particularly, the present invention relates to the phytase having (a) Theoretical molecular weight 45.5 kDa, (b) high specific activity 3960±248 U/mg, (c) high stability at high temperature and wide pH, (d) optimal pH of 4.0-5.0, (e) optimal temperature of 50-60° C., (f) high resistance to pepsin and trypsin. The phytase is very suitable to be used in feed of monogastrics as feed additive. The present invention also relates to a recombinant vector comprising said nucleic acid molecule, a recombinant host cell (e.g., Pichia pastoris) harboring said recombinant vector, and a method for producing phytase using the recombinant host cell. The present invention further provides a feed additive comprising said phytase and/or host cells expressing a phytase as effective ingredient.
    Type: Grant
    Filed: April 30, 2006
    Date of Patent: June 4, 2013
    Assignee: Feed Research Institute Chinese Academy of Agricultural Sciences
    Inventors: Bin Yao, Huiying Luo, Huoqing Huang, Yaru Wang, Tiezheng Yuan, Xiuyun Shi, Yingguo Bai, Kun Meng, Peilong Yang
  • Patent number: 8454976
    Abstract: A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.
    Type: Grant
    Filed: July 17, 2008
    Date of Patent: June 4, 2013
    Assignees: Syntaxin Limited, Health Protection Agency
    Inventors: Clifford Charles Shone, Conrad Padraig Quinn, Keith Alan Foster, John Chaddock, Philip Marks, John Sutton, Patrick Stancombe, Jonathan Wayne
  • Patent number: 8440205
    Abstract: Novel vaccines for use against ?-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against ?-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.
    Type: Grant
    Filed: March 3, 2005
    Date of Patent: May 14, 2013
    Assignee: Regents of the University of Minnesota
    Inventors: Paul Patrick Cleary, Deborah K. Stafslien
  • Patent number: 8420352
    Abstract: A novel protein delivery system to generate induced pluripotent stem (iPS) cells is described. The delivery system comprises a construct with a receptor binding domain that recognizes a receptor in a somatic cell, a translocation domain that allows the transfer of an inducer into the cytosolic space, and a cargo bearing domain to which the inducer is attached and facilitates transfer of the inducer into the cell.
    Type: Grant
    Filed: August 27, 2010
    Date of Patent: April 16, 2013
    Assignee: Synaptic Research, LLC
    Inventors: George A. Oyler, Yung-Nien Chang
  • Patent number: 8394390
    Abstract: This invention provides, among other things, proteins, polypeptides, and fragments thereof, derived from the bacteria Neisseria meningitidis B. Also provided are nucleic acids encoding for such proteins, polypeptides, and/or fragments, as well as nucleic acids complementary thereto e.g., antisense nucleic acids). Additionally, this invention provides antibodies which bind to the proteins, polypeptides, and/or fragments. This invention further provides expression vectors useful for making the proteins, polypeptides, and/or fragments, as well as host cells transformed with such vectors. This invention also provides compositions of the proteins, polypeptides, fragments, and/or nucleic acids, for use as vaccines, diagnostic reagents, immunogenic compositions, and the like. Methods of making the compositions and methods of treatment with the compositions are also provided. This invention also provides methods of detecting the proteins, polypeptides, fragments, and/or nucleic acids.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: March 12, 2013
    Assignee: Novartis AG
    Inventors: Cesira Galeotti, Guido Grandi, Vega Masignani, Mariarosa Mora, Mariagrazia Pizza, Rino Rappuoli, Guilio Ratti, Vincenzo Scarlato, Maria Scarselli
  • Patent number: 8389678
    Abstract: Disclosed are cloning and expression of a plurality of protein fragments of virB10, a Type IV Secretion System (TIVSS) in Anaplasma phagocytophilum. Such recombinant protein fragments are useful in the ELISA detection of anaplasma pathogen. The use of same as kits for ELISA is also disclosed.
    Type: Grant
    Filed: March 13, 2012
    Date of Patent: March 5, 2013
    Assignee: Medical Diagnostic Laboratories, LLC
    Inventors: John G. Hoey, Denise P. Dimitrov, Lisa B. Huang, Martin E. Adelson, Eli Mordechai
  • Patent number: 8383126
    Abstract: RP-factors, their cognate receptors, convertases, respective genes and inhibitors or mimetics thereof are described. In particular, antibodies, pharmaceutical compositions and (therapeutic, diagnostic) methods based on the RP-factors and their receptors/convertases are described.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: February 26, 2013
    Assignee: University of Wales, Aberstwyth
    Inventors: Galina V. Mukamolova, Arseny S. Kaprelyants, Danielle I. Young, Douglas B. Kell, Michael Young
  • Patent number: 8378069
    Abstract: The present invention relates to isolated polypeptides having beta-glucosidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: February 19, 2013
    Assignee: Novozymes, Inc.
    Inventors: Kristian Krogh, Paul Harris
  • Patent number: 8362206
    Abstract: The present invention provides a chimeric protein capable of killing or modifying a cell expressing abnormally high levels of a ligand of a receptor of the TNF/NGF family, comprising the amino acid sequence of at least one polypeptide consisting of an extracellular portion of said receptor connected to an effector molecule. In addition the invention provides pharmaceutical compositions comprising said chimeric protein and use thereof.
    Type: Grant
    Filed: June 28, 2005
    Date of Patent: January 29, 2013
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: David Wallach, Elena Appel, Tanya Goncahrov
  • Patent number: 8337866
    Abstract: The present invention features peptides of a PorB polypeptide, which PorB peptides are useful in production of antibodies that bind the full-length PorB polypeptide and as a therapeutic agent. In specific embodiments the invention features a composition comprising one or more PorB peptides (other than a full-length PorB polypeptide), which peptides contain at least one epitope that can elicit Chlamydia-neutralizing antibodies. The invention also features methods for induction of a protective immune response against infection by Chlamydia and Chlamydiophila.
    Type: Grant
    Filed: September 7, 2011
    Date of Patent: December 25, 2012
    Assignee: The Regents of the University of California
    Inventors: Richard S. Stephens, Diane Kawa
  • Patent number: 8287882
    Abstract: The use of flagellin and flagellin related polypectides for the protection of mammals from the effects of apoptsis is described.
    Type: Grant
    Filed: May 18, 2011
    Date of Patent: October 16, 2012
    Assignee: Cleveland Clinic Foundation
    Inventors: Andrei V. Gudkov, Joseph A. DiDonato, Vadim Krivokrysenko
  • Patent number: 8287885
    Abstract: The invention provides mutants of GAS57 which are unable to cleave IL-8 and similar substrates but which still maintain the ability to induce protection against S. pyogenes. The invention also provides antibodies which specifically bind to GAS57 and which inhibit its ability to cleave IL-8 and similar substrates. The mutants are useful, inter alia, in vaccine compositions to induce protection against S. pyogenes. The antibodies are useful, e.g., as therapeutics for treating S. pyogenes infections.
    Type: Grant
    Filed: September 12, 2008
    Date of Patent: October 16, 2012
    Assignee: Novartis AG
    Inventors: Immaculada Margarit Y Ros, Guido Grandi, Chiara Zingaretti
  • Patent number: 8273360
    Abstract: A composition comprising (a) Neisseria meningitidis serogroup B outer membrane vesicles (OMVs), and (b) an immunogenic component selected from other Neisseria proteins, or immunogenic fragments thereof. Component (b) preferably includes a protein from a different NmB strain from that from which the OMV of component (a) is derived. The OMVs are preferably obtained by deoxycholate extraction. Optionally, the composition may also comprise a protective antigen against other pathogens.
    Type: Grant
    Filed: January 17, 2001
    Date of Patent: September 25, 2012
    Assignee: Novartis AG
    Inventors: Mariagrazia Pizza, Rino Rappuoli, Marzia Monica Giuliani
  • Patent number: 8187611
    Abstract: The present invention provides a purified peptide comprising at least one of the sequences LKQKSSNSRKKRSTS (SEQ ID NO:1), or VKNKRTFLSPWISNI (SEQ ID NO:2) as well as a vaccine, a method to protect or treat an animal from anthrax toxin, a method of making a vaccine and the use of the peptide. The present invention also provides a monoclonal antibody that specifically binds to a peptide sequence comprising at least one of the following peptide sequences: LKQKSSNSRKKRSTS (SEQ ID NO:1), or VKNKRTFLSPWISNI (SEQ ID NO:2) as well as a method to protect or treat an animal from anthrax toxin, a method of making a vaccine, a pharmaceutical composition, a method of making a pharmaceutical composition, and the use of the monoclonal antibody.
    Type: Grant
    Filed: October 5, 2010
    Date of Patent: May 29, 2012
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Nareen Abboud, Arturo Casadevall
  • Patent number: 8119147
    Abstract: The present invention provides compositions including polypeptides having the characteristics of polypeptides expressed by a reference microbe such E. coli or Salmonella. Examples of Salmonella strains that can be used include, for instance, S. enterica serovar Newport, S. enterica serovar Enteritidis, S. enterica serovar Typhimurium, and S. enterica serovar Dublin. Also provided are compositions including polypeptides having a particular molecular weight and a mass fingerprint that includes polypeptide fragments having a particular set of masses, or polypeptides having an amino acid sequence with at least about 95% identity with an amino acid sequence, wherein the polypeptide has seroreactive activity. The present invention also provides methods of making and methods of using such compositions.
    Type: Grant
    Filed: September 20, 2004
    Date of Patent: February 21, 2012
    Assignee: Epitopix, LLC
    Inventors: Daryll A. Emery, Darren E. Straub, Laura Wonderling
  • Patent number: 8101194
    Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
    Type: Grant
    Filed: October 11, 2002
    Date of Patent: January 24, 2012
    Assignee: Wyeth LLC
    Inventors: Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
  • Patent number: 8088894
    Abstract: The present invention provides a Mycoplasma pneumoniae community acquired respiratory distress syndrome (CARDS) toxin, biologically active fragments/domains of the CARDS toxin, antibodies to the CARDS toxin and nucleic acids encoding the CARDS toxin. Also provided are methods of diagnosing, treating and/or preventing infection by Mycoplasma pneumoniae using the compositions provided herein.
    Type: Grant
    Filed: November 4, 2009
    Date of Patent: January 3, 2012
    Assignee: Board of Regents, The University of Texas System
    Inventors: Joel Barry Baseman, Thirumalai Rengasamy Kannan
  • Patent number: 8025885
    Abstract: The present invention provides isolated polypeptides isolatable from a Staphylococcus spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.
    Type: Grant
    Filed: September 11, 2006
    Date of Patent: September 27, 2011
    Assignee: Epitopix, LLC
    Inventors: Daryll A. Emery, Darren E. Straub, Laura Wonderling, Lisa L. Herron Olson
  • Patent number: 8025891
    Abstract: The present invention features peptides of a PorB polypeptide, which PorB peptides are useful in production of antibodies that bind the full-length PorB polypeptide and as a therapeutic agent. In specific embodiments the invention features a composition comprising one or more PorB peptides (other than a full-length PorB polypeptide), which peptides contain at least one epitope that can elicit Chlamydia-neutralizing antibodies. The invention also features methods for induction of a protective immune response against infection by Chlamydia and Chlamydophila.
    Type: Grant
    Filed: January 13, 2010
    Date of Patent: September 27, 2011
    Assignee: The Regents of the University of California
    Inventors: Richard S. Stephens, Diane Kawa
  • Patent number: RE45137
    Abstract: A combination of CpG oligonucleotides and polymer microparticles is an extremely effective adjuvant for Neisserial antigens. The invention therefore provides a composition comprising: (a) a Neisserial antigen; (b) a CpG oligonucleotide; and (c) a biodegradable polymer microparticle.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: September 16, 2014
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Derek O'Hagan, Nicholas Valiante